2017-06-01, DIZMAN, DİDEM, OZKAYA, D. B., BAHALI, A. G., DIZMAN, B. T., YILDIZ, PELİN, TOSUNER, ZEYNEP, Demirkesen, C., ONSUN, NAHİDE, SU, O., DİZMAN, DİDEM, YILDIZ, PELİN, TOSUNER, ZEYNEP, SU KÜÇÜK, ÖZLEM, ONSUN, NAHIDE

2016-11-06T00:00:00Z, YILDIZ, PELİN, SÖNMEZ, FATMA CAVİDE, TOSUNER, ZEYNEP, AYTUĞAR, EMRE, YILDIZ, PELİN

2016-12-01T00:00:00Z, CENGİZ, FATMA PELİN, EMİROĞLU, NAZAN, BIYIK ÖZKAYA, DİLEK, TOSUNER, ZEYNEP, BAHALI, ANIL GÜLSEL, SU KÜÇÜK, ÖZLEM, YILDIZ, PELİN, ONSUN, NAHİDE, CENGİZ, FATMA PELIN, EMİROĞLU, NAZAN, TOSUNER, ZEYNEP, BAHALI, ANIL GÜLSEL, SU KÜÇÜK, ÖZLEM, YILDIZ, PELİN, ONSUN, NAHIDE

2013-08-01T00:00:00Z, Sonmez, FATMA CAVİDE, Gucin, ZÜHAL, Yildiz, PELİN, Tosuner, ZEYNEP, SÖNMEZ, FATMA CAVİDE, GÜCİN, ZÜHAL, YILDIZ, PELİN, TOSUNER, ZEYNEP

Breast hamartomas are rare, benign, tumor-like nodules composed of glandular, adipose and fibrous tissue. The hamartoma was first described in 1971 as a lipofibroadenoma, fibroadenolipoma or adenolipoma, based on the predominant component of the breast tissue. Clinical findings resemble fibroadenoma and if there is a palpable mass, the patients may receive an immediate diagnosis. Ductal hyperplasia, apocrine metaplasia, calcification and adenosis may occur within the hamartoma, with rarer instances of lobular or ductal intraepithelial neoplasms. Although hamartoma is usually benign, a malignant transformation is possible. An excision and histological examination is necessary for the differential diagnosis and also for any epithelial lesions of the hamartoma. Simple excision is enough for treatment if there is no coincidental epithelial malignant lesion. The patients in the present study were treated by simple excision as there were no proliferative changes in the lesions. No recurrence or other problems were detected in the 18-month follow-up. The current study presents two cases of breast hamartoma that were diagnosed as an adenolipoma and a fibroadenolipoma, and then describes the macroscopic and microscopic observations of these lesions.

2020-10-01T00:00:00Z, YILDIZ, PELİN, SÖNMEZ, FATMA CAVİDE, TOSUNER, ZEYNEP, AYTUĞAR, EMRE, YILDIZ, PELİN

2016-12-30, CENGİZ, FATMA PELİN, EMİROĞLU, NAZAN, SU, Özlem, Tosuner, ZEYNEP, BAHALI, ANIL GÜLSEL, YILDIZ, PELİN, ONSUN, NAHİDE, CENGİZ, FATMA PELIN, EMİROĞLU, NAZAN, BIYIK ÖZKAYA, DİLEK, TOSUNER, ZEYNEP, SU KÜÇÜK, ÖZLEM, BAHALI, ANIL GÜLSEL, YILDIZ, PELİN, ONSUN, NAHIDE

2014-12-01T00:00:00Z, TOSUNER, ZEYNEP, ARICI, Dilek Sema, GÜCİN, ZÜHAL, BÜYÜKPINARBAŞILI, NUR, SÖNMEZ, FATMA CAVİDE, YILDIZ, PELİN, TOSUNER, ZEYNEP, ARICI, DILEK SEMA, GÜCİN, ZÜHAL, BÜYÜKPINARBAŞILI, NUR, SÖNMEZ, FATMA CAVİDE, YILDIZ, PELİN

Objective: Thyroid transcription factor-1 (TTF-1) immunoexpression is frequently determined in small-cell lung carcinomas, as well as primary lung adenocarcinomas. While dealing with metastatic carcinomas, TTF-1 immunoexpression is a significant indicator of primary lung carcinomas. Recent studies have revealed that TTF-1 immunoexpression is also defined in non-lung cancers, such as squamous cell carcinomas of different sites and certain neuroendocrine tumors. The verified data obtained from these studies indicate that a straightforward diagnosis of primary lung carcinoma in cases with positive TTF-1 immunoexpression can cause diagnostic contradictions. The aim of our study is to investigate the immunoexpression status of TTF-1 in common non-lung tumors. Methods: A total of 85 cases that were diagnosed in our institute between the years 2011-2012 were included in our study. After a review of the pathological slides prepared from these tumors [colon adenocarcinoma (n: 15), renal cell carcinoma (n: 15), prostate adenocarcinoma (n: 15), invasive papillary urothelial carcinoma (n: 15), invasive ductal carcinoma of breast (n: 15), and neuroendocrine tumors (n: 10)] TTF-1 immunohistochemistry was applied. Semiquantative evaluation based on the distribution and intensity of the staining was performed by two pathologists, respectively. Results: Positive immunostaining was evident in only 1 case of colon adenocarcinoma out of 85 cases. Conclusion: Our study demonstrated that TTF-1 immunoexpression is a very rare finding (1%) in non-lung tumors. This result provides that anti-TTF-1 is a reliable antibody in the interpretation of primary lung carcinomas. In fact, further studies with a large number of cases are needed to confirm the sensitivity and specificity of TTF-1.

2014-06-01T00:00:00Z, Yildiz, PELİN, Tosuner, ZEYNEP, Guneren, ETHEM, Demirkesen, Cuyan, YILDIZ, PELİN, TOSUNER, ZEYNEP, GÜNEREN, ETHEM

Primary cutaneous carcinosarcomas (CS) are extremely rare biphasic tumors mainly located on sun-exposed areas of the body. Two hypotheses-multiclonal (convergence) and monoclonal (divergence)-have been suggested for the evolution of these tumors. According to multiclonal hypothesis two or more stem cells of epithelial and mesenchymal origin give rise to these tumors, while a single totipotential cell differentiate into epithelial and mesenchymal components, either synchronously or metachronously according to monoclonal hypothesis. Cutaneous CSs are subdivided into two distinct groups as epidermal and adnexal CSs, due to their epithelial content. We present an interesting case of cutaneous adnexal CS, showing peripheral nerve sheath differentiation and having the spiradenocarcinoma component derived from spiradenoma. To the best of our knowledge, it is the first reported case of CS with these features in the literature.

2017-05-06T00:00:00Z, DİZMAN, DİDEM, BIYIK ÖZKAYA, DİLEK, BAHALI, ANIL GÜLSEL, TOPUKÇU, BUĞÇE, YILDIZ, PELİN, TOSUNER, ZEYNEP, DEMİRKESEN, CÜYAN, ONSUN, NAHİDE, SU KÜÇÜK, ÖZLEM SU, BAHALI, ANIL GÜLSEL, YILDIZ, PELİN, ONSUN, NAHIDE, SU KÜÇÜK, ÖZLEM

2016-12-01, CENGİZ, FATMA PELİN, EMİROĞLU, NAZAN, BIYIK ÖZKAYA, DİLEK, TOSUNER, ZEYNEP, BAHALI, ANIL GÜLSEL, YILDIZ, PELİN, ONSUN, NAHİDE, CENGİZ, FATMA PELIN, EMİROĞLU, NAZAN, BIYIK ÖZKAYA, DİLEK, TOSUNER, ZEYNEP, SU KÜÇÜK, ÖZLEM, BAHALI, ANIL GÜLSEL, YILDIZ, PELİN, ONSUN, NAHIDE